Navigation Links
Scientists creating new diagnostic and bioinformatics tools for psychotic disorders
Date:9/16/2013

A new EU project, METSY, develops and applies neuroimaging and bioinformatics tools to study how lipid metabolism is connected to psychotic disorders and metabolic co-morbidities such as metabolic syndrome and diabetes.

The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging biomarkers that have diagnostic potential for prediction and monitoring psychotic disorders and associated metabolic co-morbidities. The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.

The 4-year EU-project is coordinated by Research Professor Matej Oreič from VTT Technical Research Centre of Finland. Total budget for the project is 5.94 million , of which the EU's share is 4.23 million.

Project partners: VTT Technical Research Centre of Finland, Biomax Informatics AG (Germany), Servicio Madrileo de Salud (Spain), University of Turku (Finland), National Institute for Health and Welfare (Finland), Philips Research (Germany), King's College London (UK).


'/>"/>

Contact: Matej Orešič
matej.oresic@vtt.fi
358-207-224-491
VTT Technical Research Centre of Finland
Source:Eurekalert

Page: 1

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. WileyChina.com - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... 2016 Research and Markets has announced the ... report to their offering. ... The ... 2021 from USD 6.21 Billion in 2016, growing at a CAGR ... the bioinformatics market is driven by the growing demand for nucleic ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... Equicare Health Inc ., the leading supplier of comprehensive ... the top 100 companies in the 2016 Global Digital ... top digital health companies across the globe.   ... continually upgrading our product with the ongoing digital shift ... Len Grenier , CEO of Equicare Health, "It,s ...
(Date:11/30/2016)... Part of 5m$ Investment in Integrated Drug Discovery ... , ... announced that it had successfully completed the expansion of their ... the Screening Collection to over 400,000. The new compounds were ... company. This expansion, complemented by new robotics and compound management ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the development of a new orally administered treatment for Alzheimer’s disease (AD), today ... of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s ...
Breaking Biology Technology: